TGA / PMDA / NMPA · Asia-Pacific
induction — TGA / PMDA / NMPA regulatory status
induction regulatory status in the Asia-Pacific is tracked from public TGA / PMDA / NMPA records and cross-linked clinical and patent datasets on NovaPharmaNews. Current status: NMPA clinical trials.
Status snapshot
- Status
- NMPA clinical trials
- Structured fields
- 4
Regional decision snapshot — NMPA: clinical trials.
Linked evidence on this spoke: 34 published clinical programs and 12 related patent records. Use the tables below for NCT identifiers, phases, and exclusivity dates; verify against primary sources before BD or medical decisions.
Regulatory timeline
| Regulator | Region | Status | Date | Source |
|---|---|---|---|---|
| NMPA | China | clinical trials | — | Evidence |
Linked clinical programs
| Program | Phase | Sponsor | NCT |
|---|---|---|---|
| 2 cycles induction chemotherapy | Phase 3 | First People's Hospital | NCT05860868 |
| 2215-CL-0201 | Phase 3 | Astellas Pharma | 2024-512474-98-00 |
| APHP240909 | Phase 3 | PARItec | 2025-521331-36-00 |
| HM16/047 | Phase 3 | Takeda | NCT03562169 |
| Induction Chemotherapy | Phase 3 | First People's Hospital | NCT05062005 |
| JPB898 (Induction and Maintenance) | Phase 3 | Sandoz (Japan) | NCT06587451 |
| MyelomaXIV | Phase 3 | Takeda | NCT03720041 |
| PF-06651600 Induction Dose | Phase 3 | Pfizer | NCT03732807 |
| gemcitabine and cisplatin (Induction chemotherapy) | Phase 3 | Sun Yat-sen University | NCT05979961 |
| gemcitabine and cisplatin (Induction chemotherapy) | Phase 3 | Chinese Academy of | NCT01872962 |
| misoprostol | Phase 3 | Chinese Academy of | NCT00529295 |
| 20170104 | Phase 2 | Amgen | 2023-506004-93-00 |
Related patents
| Number | Title | Jurisdiction |
|---|---|---|
| 2025169901 | CONJUGUÉ ANTICORPS-MÉDICAMENT CONTENANT UN COMPOSÉ HÉTÉROCYCLIQUE PRÉSENTANT UNE ACTIVITÉ D'INDUCTION DE LA DÉCOMPOSITION DE PROTÉINES MUTANTES KRAS | WO |
| 12310986 | Compositions and methods for the treatment of cancer cells by induction of cytotoxic oxidative stress | US |
| 2025058008 | CONJUGUÉ ANTICORPS-MÉDICAMENT CONTENANT UN COMPOSÉ HÉTÉROCYCLIQUE AYANT POUR ACTIVITÉ L'INDUCTION DE LA DÉCOMPOSITION DE LA PROTÉINE KRAS MUTANTE G12D | WO |
| 11873319 | Cyclic di-nucleotide induction of type I interferon | US |
| 11781110 | Induction of corneal endothelial cells | US |
| 11083801 | Factor VIII mutation repair and tolerance induction | US |
| 11065330 | Induction of antigen-specific tolerance by peripheral phagocytosis | US |
| 10980841 | Methods and compositions for in vivo induction of pancreatic beta cell formation | US |
| 10293002 | Methods and compositions for in vivo induction of pancreatic beta cell formation | US |
| 10272163 | Factor VIII mutation repair and tolerance induction | US |
| 10155014 | Cyclic di-AMP induction of type I interferon | US |
| 9763987 | Cyclic di-AMP induction of type I interferon | US |
Related hubs
FAQ
What is the TGA / PMDA / NMPA approval status of induction?
induction currently shows NMPA clinical trials in our Asia-Pacific regulatory index. Confirm on the official TGA / PMDA / NMPA label or EPAR before clinical or commercial use.
Where does NovaPharmaNews get induction regulatory data?
Status fields are joined from public sources (openFDA / EMA / regional agencies), ClinicalTrials.gov-linked programs, and patent registries. See /about/data-sources for attribution.
How many clinical programs are linked to induction?
This spoke lists 34 published programs associated with induction in our pipeline index.